1
|
Gharibkandi NA, Wawrowicz K, Walczak R, Majkowska-Pilip A, Wierzbicki M, Bilewicz A. 109Pd/ 109mAg in-vivo generator in the form of nanoparticles for combined β - - Auger electron therapy of hepatocellular carcinoma. EJNMMI Radiopharm Chem 2024; 9:59. [PMID: 39136900 PMCID: PMC11322470 DOI: 10.1186/s41181-024-00293-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Accepted: 08/06/2024] [Indexed: 08/16/2024] Open
Abstract
BACKGROUND Convenient therapeutic protocols for hepatocellular carcinoma (HCC) are often ineffective due to late diagnosis and high tumor heterogeneity, leading to poor long-term outcomes. However, recently performed studies suggest that using nanostructures in liver cancer treatment may improve therapeutic effects. Inorganic nanoparticles represent a unique material that tend to accumulate in the liver when introduced in-vivo. Typically, this is a major drawback that prevents the therapeutic use of nanoparticles in medicine. However, in HCC tumours, this may be advantageous because nanoparticles may accumulate in the target organ, where the leaky vasculature of HCC causes their accumulation in tumour cells via the EPR effect. On the other hand, recent studies have shown that combining low- and high-LET radiation emitted from the same radionuclide, such as 161Tb, can increase the effectiveness of radionuclide therapy. Therefore, to improve the efficacy of radionuclide therapy for hepatocellular carcinoma, we suggest utilizing radioactive palladium nanoparticles in the form of 109Pd/109mAg in-vivo generator that simultaneously emits β- particles and Auger electrons. RESULTS Palladium nanoparticles with a size of 5 nm were synthesized using 109Pd produced through neutron irradiation of natural palladium or enriched 108Pd. Unlike the 109Pd-cyclam complex, where the daughter radionuclide diffuses away from the molecules, 109mAg remains within the nanoparticles after the decay of 109Pd. In vitro cell studies using radioactive 109Pd nanoparticles revealed that the nanoparticles accumulated inside cells, reaching around 50% total uptake. The 109Pd-PEG nanoparticles exhibited high cytotoxicity, even at low levels of radioactivity (6.25 MBq/mL), resulting in almost complete cell death at 25 MBq/mL. This cytotoxic effect was significantly greater than that of PdNPs labeled with β- (131I) and Auger electron emitters (125I). The metabolic viability of HCC cells was found to be correlated with cell DNA DSBs. Also, successful radioconjugate anticancer activity was observed in three-dimensional tumor spheroids, resulting in a significant treatment response. CONCLUSION The results indicate that nanoparticles labeled with 109Pd can be effectively used for combined β- - Auger electron-targeted radionuclide therapy of HCC. Due to the decay of both components (β- and Auger electrons), the 109Pd/109mAg in-vivo generator presents a unique potential in this field.
Collapse
Affiliation(s)
- Nasrin Abbasi Gharibkandi
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St, Warsaw, 03-195, Poland
| | - Kamil Wawrowicz
- Department of Medical Physics, M. Smoluchowski Institute of Physics, Faculty of Physics, Astronomy and Applied Computer Science, Jagiellonian University, Kraków, Poland
- Center for Theranostics, Jagiellonian University, Kraków, Poland
| | - Rafał Walczak
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St, Warsaw, 03-195, Poland
| | - Agnieszka Majkowska-Pilip
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St, Warsaw, 03-195, Poland.
- Department of Nuclear Medicine, National Medical Institute of the Ministry of the Interior and Administration, Wołoska 137 St, Warsaw, 02-507, Poland.
| | - Mateusz Wierzbicki
- Institute of Biology, Warsaw University of Life Sciences, Ciszewskiego 8 St, Warsaw, 02-786, Poland
| | - Aleksander Bilewicz
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St, Warsaw, 03-195, Poland.
| |
Collapse
|
2
|
Hojorat M, Pineau J, Driver CHS, Esteban-Gómez D, Cordier M, Zeevaart JR, Platas-Iglesias C, Lima LMP, Le Bris N, Tripier R. Relevance of Oxocyclam from Palladium(II) Coordination to Radiopharmaceutical Development. Inorg Chem 2024; 63:11884-11896. [PMID: 38861670 DOI: 10.1021/acs.inorgchem.4c01780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2024]
Abstract
We provide a comprehensive study of the coordination of oxocyclam with palladium(II), including presentation of a novel bifunctional analogue, p-H2N-Bn-oxocyclam, bearing an aniline pendant. The complexation of palladium(II) with oxocyclam was examined by various techniques, including NMR analysis and potentiometric titrations which revealed that the Pd(II) complex can adopt different configurations such as trans-I and trans-III. In addition, oxocyclam forms a thermodynamically stable palladium(II) complex, the stabilization being attributed to the deprotonation of the amide function. The crystal structures of [Pd(H-1oxocyclam)]+ and [Pd(oxocyclam)]2+ were obtained, revealing the structural details previously anticipated, including, in the second case, the presence of the proton on the carbonyl oxygen atom. Additionally, the study explored the redox behavior of the Pd(II)-oxocyclam complex through reduction and oxidation voltammograms at different pH values. Successful 109Pd-labeling of oxocyclam and p-H2N-Bn-oxocyclam at pH 3.5 demonstrated high labeling efficiencies, whatever the species formed. The stability of the radiocomplexes was assessed and moderate transchelation toward EDTA was observed. Overall, oxocyclam displayed favorable properties for Pd(II) coordination and radiolabeling, suggesting its potential as a chelating agent for this metal in palladium-based applications.
Collapse
Affiliation(s)
- Maher Hojorat
- UMR CNRS 6521 CEMCA, Université de Brest, 6 Avenue Victor le Gorgeu, 29238 Brest, France
| | - Julie Pineau
- UMR CNRS 6521 CEMCA, Université de Brest, 6 Avenue Victor le Gorgeu, 29238 Brest, France
| | - Cathryn H S Driver
- South African Nuclear Energy Corporation, Radiochemistry and PreClinical Imaging Facility, Elias Motsoaledi Street, R104 Pelindaba, Pretoria 0240, North West, South Africa
| | - David Esteban-Gómez
- Departamento de Química, Facultade de Ciencias & Centro Interdisciplinar de Química e Bioloxía (CICA), Universidade da Coruña, 15071 A Coruña, Spain
| | - Marie Cordier
- CNRS, ISCR (Institut des Sciences Chimiques de Rennes) UMR 6226, Univ Rennes, 35000 Rennes, France
| | - Jan Rijn Zeevaart
- South African Nuclear Energy Corporation, Radiochemistry and PreClinical Imaging Facility, Elias Motsoaledi Street, R104 Pelindaba, Pretoria 0240, North West, South Africa
| | - Carlos Platas-Iglesias
- Departamento de Química, Facultade de Ciencias & Centro Interdisciplinar de Química e Bioloxía (CICA), Universidade da Coruña, 15071 A Coruña, Spain
| | - Luís M P Lima
- Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, 2780-157 Oeiras, Portugal
| | - Nathalie Le Bris
- UMR CNRS 6521 CEMCA, Université de Brest, 6 Avenue Victor le Gorgeu, 29238 Brest, France
| | - Raphaël Tripier
- UMR CNRS 6521 CEMCA, Université de Brest, 6 Avenue Victor le Gorgeu, 29238 Brest, France
| |
Collapse
|
3
|
Sakr TM, Elsabagh MF, Fayez H, Sarhan MO, Syam YM, Anwar MM, Motaleb MA, Zaghary WA. Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation. Daru 2024; 32:77-95. [PMID: 38072913 PMCID: PMC11087444 DOI: 10.1007/s40199-023-00487-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Accepted: 10/10/2023] [Indexed: 05/12/2024] Open
Abstract
BACKGROUND In this study, a combination of nanotechnology, organic synthesis and radiochemistry were utilized in order to design an efficient nano-system conjugated with a suitable radionuclide and an antitumor agent for possible application as tumor theragnostic agent. METHOD Four novel compounds (3 and 4a-c) bearing tetrahydroquinazoline-7-sulfonohydrazide or 1,2,3,4-tetrahydroquinazoline-7-sulfonamide scaffold were designed. Then, docking study predicted that the compounds can be considered as potential inhibitors for PARP-1. Following that; the four compounds were synthesized and properly characterized using 1HNMR, 13CNMR, IR and Mass spectroscopy. The cytotoxic effect of the four compounds was evaluated against breast cancer cell line (MDA-MB-436), where compound 3 showed the most promising cytotoxic effect. The inhibitory effect of the four compounds was evaluated in vitro against PARP-1. RESULT Carboxylated graphene oxide nanosheets (NGO-COOH) were synthesized by a modified Hummer's method and has size of range 40 nm. The NGO-COOH nanosheets were proven to be safe and biocompatible when tested in vitro against normal human lung fibroblast cells (MRC-5). The prepared NGO-COOH nanosheets were conjugated with compound 3 then radiolabeled with 99mTc to yield 99mTc-NGO-COOH-3 with a radiochemical yield of 98.5.0 ± 0.5%. 99mTc-NGO-COOH-3 was injected intravenously in solid tumor bearing mice to study the degree of localization of the nano-system at tumor tissue. The results of the study revealed, excellent localization and retention of the designed nano-system at tumor tissues with targeting ratio of 9.0. CONCLUSION Stirred a new candidate tumor theragnostic agent that is safe, selective and stable.
Collapse
Affiliation(s)
- Tamer M Sakr
- Radioisotopes Production Facility, Second Egyptian Research Reactor Complex, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
- Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Mohammed F Elsabagh
- Radioisotopes Production Facility, Second Egyptian Research Reactor Complex, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt.
| | - Hend Fayez
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Mona O Sarhan
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Yasmin M Syam
- Department of Therapeutic Chemistry/ National Research Centre, Cairo, Egypt
| | - Manal M Anwar
- Department of Therapeutic Chemistry/ National Research Centre, Cairo, Egypt
| | - Mohammed A Motaleb
- Labeled Compounds Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, 13759, Egypt
| | - Wafaa A Zaghary
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt
| |
Collapse
|
4
|
Kumar N, Sharma AK, Guleria M, Shelar SB, Chakraborty A, Rakshit S, Kolay S, Satpati D, Das T. Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation. Mol Pharm 2024; 21:2351-2364. [PMID: 38477252 DOI: 10.1021/acs.molpharmaceut.3c01152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2024]
Abstract
The objective of the present work was to evaluate the potential of a nuclear localization signal (NLS) toward facilitating intracellular delivery and enhancement in the therapeutic efficacy of the molecular cargo. Toward this, an in-house synthesized porphyrin derivative, namely, 5-carboxymethyelene-oxyphenyl-10,15,20-tris(4-methoxyphenyl) porphyrin (UTriMA), was utilized for conjugation with the NLS sequence [PKKKRKV]. The three compounds synthesized during the course of the present work, namely DOTA-Lys-NLS, DOTA-UTriMA-Lys-NLS, and DOTA-Lys-UTriMA, were evaluated for cellular toxicity in cancer cell lines (HT1080), wherein all exhibited minimal dark toxicity. However, during photocytotoxicity studies with DOTA-Lys-UTriMA and DOTA-UTriMA-Lys-NLS conjugates in the same cell line, the latter exhibited significantly higher light-dependent toxicity compared to the former. Furthermore, the photocytotoxicity for DOTA-UTriMA-Lys-NLS in a healthy cell line (WI26VA4) was found to be significantly lower than that observed in the cancer cells. Fluorescence cell imaging studies carried out in HT1080 cancer cells revealed intracellular accumulation for the NLS-conjugated porphyrin (DOTA-UTriMA-Lys-NLS), whereas unconjugated porphyrin (DOTA-Lys-UTriMA) failed to do so. To evaluate the radiotherapeutic effects of the synthesized conjugates, all three compounds were radiolabeled with 177Lu, a well-known therapeutic radionuclide with high radiochemical purity (>95%). During in vitro studies, the [177Lu]Lu-DOTA-UTriMA-Lys-NLS complex exhibited the highest cell binding as well as internalization among the three radiolabeled complexes. Biological distribution studies for the radiolabeled compounds were performed in a fibrosarcoma-bearing small animal model, wherein significantly higher accumulation and prolonged retention of [177Lu]Lu-DOTA-UTriMA-Lys-NLS (9.32 ± 1.27% IA/g at 24 h p.i.) in the tumorous lesion compared to [177Lu]Lu-UTriMA-Lys-DOTA (2.3 ± 0.13% IA/g at 24 h p.i.) and [177Lu]Lu-DOTA-Lys-NLS complexes (0.26 ± 0.17% IA/g at 24 h p.i.) were observed. The results of the biodistribution studies were further corroborated by recording serial SPECT-CT images of fibrosarcoma-bearing Swiss mice administered with [177Lu]Lu-DOTA-UTriMA-Lys-NLS at different time points. Tumor regression studies performed with [177Lu]Lu-DOTA-UTriMA-Lys-NLS in the same animal model with two different doses [250 μCi (9.25 MBq) and 500 μCi (18.5 MBq)] resulted in a significant reduction in tumor mass in the treated group of animals. The above results revealed a definite enhancement in the targeting ability of molecular cargo upon conjugation with NLS and hence indicated that this strategy may be helpful for the preparation of drug-NLS conjugates as multimodal agents.
Collapse
Affiliation(s)
- Naveen Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Amit K Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Sandeep B Shelar
- Chemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Soumi Kolay
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Drishty Satpati
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| |
Collapse
|
5
|
Gharibkandi NA, Wawrowicz K, Majkowska-Pilip A, Żelechowska-Matysiak K, Wierzbicki M, Bilewicz A. Au@ 109Pd core-shell nanoparticle conjugated to trastuzumab for the therapy of HER2+ cancers: studies on the applicability of 109Pd/ 109mAg in vivo generator in combined β - auger electron therapy. EJNMMI Radiopharm Chem 2023; 8:26. [PMID: 37821747 PMCID: PMC10567614 DOI: 10.1186/s41181-023-00212-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Accepted: 10/03/2023] [Indexed: 10/13/2023] Open
Abstract
BACKGROUND In radionuclide therapy, to enhance therapeutic efficacy, an intriguing alternative is to ensure the simultaneous implementation of low- and high-LET radiation emitted from a one radionuclide. In the present study, we introduce the concept of utilizing 109Pd (T1/2 = 13.7 h) in the form of a 109Pd/109mAg in vivo generator. In this system, 109Pd emits beta particles of medium energy, while 109mAg releases a cascade of conversion and Auger electrons. 109Pd was utilized in the form of 15 nm gold nanoparticles, which were coated with a monolayer of 109Pd. In this system, the 109Pd atoms are on the surface of the nanoparticle, while the 109mAg atoms generated in the decay reaction possess the capability for unhindered emission of Auger electrons. RESULTS 109Pd, obtained through neutron irradiation of natural palladium, was deposited onto 15-nm gold nanoparticles, exceeding a efficiency rate of 95%. In contrast to previously published data on in vivo generators based on chelators, where the daughter radionuclide diffuses away from the molecules, daughter radionuclide 109mAg remains on the surface of gold nanoparticles after the decay of 109Pd. To obtain a radiobioconjugate with an affinity for HER2 receptors, polyethylene glycol chains and the monoclonal antibody trastuzumab were attached to the Au@Pd nanoparticles. The synthesized bioconjugate contained an average of 9.5 trastuzumab molecules per one nanoparticle. In vitro cell studies indicated specific binding of the Au@109Pd-PEG-trastuzumab radiobioconjugate to the HER2 receptor on SKOV-3 cells, resulting in 90% internalization. Confocal images illustrated the accumulation of Au@109Pd-PEG-trastuzumab in the perinuclear area surrounding the cell nucleus. Despite the lack of nuclear localization, which is necessary to achieve an effective cytotoxic effect of Auger electrons, a substantial cytotoxic effect, significantly greater than that of pure β- and pure Auger electron emitters was observed. We hypothesize that in the studied system, the cytotoxic effect of the Auger electrons could have also occurred through the damage to the cell's nuclear membrane by Auger electrons emitted from nanoparticles accumulated in the perinuclear area. CONCLUSION The obtained results show that trastuzumab-functionalized 109Pd-labeled nanoparticles can be suitable for the application in combined β--Auger electron targeted radionuclide therapy. Due to both components decay (β- and conversion/Auger electrons), the 109Pd/109mAg in vivo generator presents unique potential in this field. Despite the lack of nuclear localization, which is highly required for efficient Auger electron therapy, an adequate cytotoxic effect was attained.
Collapse
Affiliation(s)
- Nasrin Abbasi Gharibkandi
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland
| | - Kamil Wawrowicz
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland
- Center for Theranostics, Jagiellonian University, Kopernika 40 St., 31-501, Cracow, Poland
| | - Agnieszka Majkowska-Pilip
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland
- Department of Nuclear Medicine, Central Clinical Hospital of the Ministry of the Interior and Administration, Wołoska 137 St., Warsaw, 02-507, Poland
| | - Kinga Żelechowska-Matysiak
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland
| | - Mateusz Wierzbicki
- Institute of Biology, Warsaw University of Life Sciences, Ciszewskiego 8 St., 02-786, Warsaw, Poland
| | - Aleksander Bilewicz
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 St., 03-195, Warsaw, Poland.
| |
Collapse
|
6
|
Gandidzanwa S, Beukes N, Joseph SV, Janse Van Vuuren A, Mashazi P, Britton J, Kilian G, Roux S, Nyokong T, Lee ME, Frost CL, Tshentu ZR. The development of folate-functionalised palladium nanoparticles for folate receptor targeting in breast cancer cells. NANOTECHNOLOGY 2023; 34:465705. [PMID: 37527629 DOI: 10.1088/1361-6528/acec52] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 08/01/2023] [Indexed: 08/03/2023]
Abstract
Folate receptor-targeted therapy has excellent prospects for the treatment of breast cancer. A non-toxic concentration of folate-conjugated palladium-based nanoparticles was used to target the overexpressed folate receptor on breast cancer cells. The folate-conjugated nanoparticles were tailored to accumulate selectively in cancer cells relative to normal cells via the folate receptor. The MDA-MB-231, MDA-MB-468, MCF-7 breast cancer cell lines, and MCF-10A normal cell lines were used in the study. Qualitative and quantitative analysis of nanoparticle cellular uptake and accumulation was conducted using transmission electron microscopy and inductively coupled plasma-optical emission spectroscopy. The findings proved that folate-conjugated palladium nanoparticles successfully and preferentially accumulated in breast cancer cells. We conclude that folate-conjugated palladium nanoparticles can be potentially used to target breast cancer cells for radiopharmaceutical applications.
Collapse
Affiliation(s)
| | - Natasha Beukes
- Department of Biochemistry and Microbiology, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Sinelizwi V Joseph
- Department of Chemistry, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Arno Janse Van Vuuren
- Center for High Resolution Transmission Electron Microscopy, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Philani Mashazi
- Department of Chemistry, Rhodes University, Makhanda 6140, South Africa
- Institute of Nanotechnology Innovation, Rhodes University, Makhanda 6140, South Africa
| | - Jonathan Britton
- Institute of Nanotechnology Innovation, Rhodes University, Makhanda 6140, South Africa
| | - Gareth Kilian
- Department of Pharmacy, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Saartjie Roux
- Department of Human Physiology, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Tebello Nyokong
- Institute of Nanotechnology Innovation, Rhodes University, Makhanda 6140, South Africa
| | - Michael E Lee
- Center for High Resolution Transmission Electron Microscopy, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Carminita L Frost
- Department of Biochemistry and Microbiology, Nelson Mandela University, Gqeberha 6001, South Africa
| | - Zenixole R Tshentu
- Department of Chemistry, Nelson Mandela University, Gqeberha 6001, South Africa
| |
Collapse
|
7
|
Kumar N, Guleria M, Shelar S, Amirdhanayagam J, Das T. Copper metal insertion in porphyrin core compromises the photocytotoxicity of free base porphyrin: Revelation during synthesis of natCu/[64Cu]Cu-porphyrin complex. J Photochem Photobiol A Chem 2023. [DOI: 10.1016/j.jphotochem.2023.114754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
|
8
|
Measurement of the integrated cross section of 110Pd(γ,n)109mPd, 110Pd(γ,n)109gPd, and 110Pd(γ,x)108mRh reactions with 70 MeV bremsstrahlung. Radiat Phys Chem Oxf Engl 1993 2023. [DOI: 10.1016/j.radphyschem.2022.110598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
9
|
Guleria M, Suman SK, Kumar N, Sharma AK, Amirdhanayagam J, Sarma HD, Satpati D, Das T. Evaluation of the effect of a cell penetrating peptide (TAT) towards tailoring the targeting efficacy and tumor uptake of porphyrin. RSC Med Chem 2022; 13:1378-1390. [PMID: 36439980 PMCID: PMC9667781 DOI: 10.1039/d2md00097k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 08/08/2022] [Indexed: 08/13/2023] Open
Abstract
Cell penetrating peptides (CPPs) are known to possess a unique capacity to penetrate biological membranes and translocate various molecules into the cells. Therefore, porphyrin-CPP conjugates could be envisaged to boost the intracellular delivery of porphyrins thereby providing an improved tool for the development of agents for multi-modal applications for cancer management. Working in this direction, an unsymmetrically substituted porphyrin derivative was conjugated with a transactivating transcriptional activator peptide (TAT) and various in vitro and in vivo studies were carried out in order to study the effect of adding a CPP to the porphyrin derivative. MTT assay revealed the preferential light dependent toxicity of the porphyrin derivative which was further enhanced upon peptide conjugation. Fluorescence and flow cytometry studies revealed the relatively higher cellular internalization of the porphyrin-TAT conjugate in comparison with the porphyrin derivative. The elevated light dependent cell toxicity of the porphyrin-TAT conjugate along with its capability of generating cytotoxic singlet oxygen indicated the advantages of using the porphyrin-TAT conjugate for PDT applications. Also, porphyrin and the porphyrin-peptide conjugate were radiolabelled with 68Ga to investigate their possible potential as PET agents. In vivo biodistribution studies revealed a higher tumor uptake for the 68Ga-porphyrin-TAT conjugate (6.32 ± 1.24% IA per g) than for 68Ga-porphyrin (2.45 ± 0.88% IA per g) at 60 min post-administration. However, the observation of a higher non-target retention of the radiolabelled agents during in vivo studies might pose a limitation on their possible application in PET imaging.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Shishu K Suman
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Naveen Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Amit K Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India
| | - Drishty Satpati
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| |
Collapse
|
10
|
Moghassemi S, Dadashzadeh A, de Azevedo RB, Amorim CA. Secure transplantation by tissue purging using photodynamic therapy to eradicate malignant cells. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY. B, BIOLOGY 2022; 234:112546. [PMID: 36029759 DOI: 10.1016/j.jphotobiol.2022.112546] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 08/07/2022] [Accepted: 08/16/2022] [Indexed: 12/17/2022]
Abstract
The field of photodynamic therapy (PDT) for treating various malignant neoplasms has been given researchers' attention due to its ability to be a selective and minimally invasive cancer therapy strategy. The possibility of tumor cell infection and hence high recurrence rates in cancer patients tends to restrict autologous transplantation. So, the photodynamic tissue purging process, which consists of selective photoinactivation of the malignant cells in the graft, is defined as a compromising strategy to purify contaminated tissues before transplantation. In this strategy, the direct malignant cells' death results from the reactive oxygen species (ROS) generation through the activation of a photosensitizer (PS) by light exposure in the presence of oxygen. Since new PS generations can effectively penetrate the tissue, PDT could be an ideal ex vivo tissue purging protocol that eradicates cancer cells derived from various malignancies. The challenge is that the applied pharmacologic ex vivo tissue purging should efficiently induce tumor cells with minor influence on normal tissue cells. This review aims to provide an overview of the current status of the most effective PDT strategies and PS development concerning their potential application in ex vivo purging before hematopoietic stem cell or ovarian tissue transplantation.
Collapse
Affiliation(s)
- Saeid Moghassemi
- Pôle de Recherche en Physiopathologie de la Reproduction, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - Arezoo Dadashzadeh
- Pôle de Recherche en Physiopathologie de la Reproduction, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - Ricardo Bentes de Azevedo
- Laboratory of Nanobiotechnology, Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasília, Brasília DF, Brazil
| | - Christiani A Amorim
- Pôle de Recherche en Physiopathologie de la Reproduction, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium.
| |
Collapse
|
11
|
Pineau J, Lima LMP, Platas‐Iglesias C, Zeevaart JR, Driver CHS, Le Bris N, Tripier R. Relevance of Palladium to Radiopharmaceutical Development Considering Enhanced Coordination Properties of TE1PA. Chemistry 2022; 28:e202200942. [PMID: 35560962 PMCID: PMC9401000 DOI: 10.1002/chem.202200942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Indexed: 11/09/2022]
Abstract
The limited use of palladium‐103 and ‐109 radionuclides for molecular radiotherapy is surely due to the lack of appropriate ligands capable of fulfilling all criteria required for application in nuclear medicine. Furthermore, the thermodynamic properties of these complexes in solution remain difficult to establish. The challenge is compounded when considering that radiolabeling of compounds for translation to clinical trials requires fast complexation. Thus, the coordination of Pd(II) and 103/109Pd‐nuclides is a huge challenge in terms of molecular design and physicochemical characterization. Herein, we report a comprehensive study highlighting TE1PA, a monopicolinate cyclam – already established in nuclear imaging with 64Cu‐PET (positron emission tomography) imaging tracers – as a highly relevant chelator for natural Pd and subsequently 109Pd‐nuclide. The structural, thermodynamic, kinetic and radiolabeling studies of Pd(II) with TE1PA, as well as the comparison of this complex with three structurally related derivatives, support palladium‐TE1PA radiopharmaceuticals as leading candidates for targeted nuclear medicine.
Collapse
Affiliation(s)
- Julie Pineau
- Univ Brest, UMR CNRS 6521 CEMCA 6 avenue Victor le Gorgeu 29238 Brest France) E-mail: s
| | - Luís M. P. Lima
- Instituto de Tecnologia Química e Biológica António Xavier Universidade Nova de Lisboa Av. da República 2780-157 Oeiras Portugal
| | - Carlos Platas‐Iglesias
- Departamento de Química Facultade de Ciencias & Centro de Investigaciones Científicas Avanzadas (CICA) Universidade da Coruña San Vicente de Elviña 15071 A Coruña Spain
| | - Jan Rijn Zeevaart
- South African Nuclear Energy Corporation Radiochemistry and PreClinical Imaging Facility Elias Motsoaledi Street, R104 Pelindaba North West 0240 South Africa
| | - Cathryn H. S. Driver
- South African Nuclear Energy Corporation Radiochemistry and PreClinical Imaging Facility Elias Motsoaledi Street, R104 Pelindaba North West 0240 South Africa
| | - Nathalie Le Bris
- Univ Brest, UMR CNRS 6521 CEMCA 6 avenue Victor le Gorgeu 29238 Brest France) E-mail: s
| | - Raphaël Tripier
- Univ Brest, UMR CNRS 6521 CEMCA 6 avenue Victor le Gorgeu 29238 Brest France) E-mail: s
| |
Collapse
|
12
|
Le Bris N, Pineau J, Lima LM, Tripier R. Palladium(II) coordination with polyazacycloalkanes. Coord Chem Rev 2022. [DOI: 10.1016/j.ccr.2021.214343] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Jiang YW, Gao G, Jia HR, Zhang X, Cheng X, Wang HY, Liu P, Wu FG. Palladium Nanosheets as Safe Radiosensitizers for Radiotherapy. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2020; 36:11637-11644. [PMID: 32902987 DOI: 10.1021/acs.langmuir.0c02316] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Many noble metal-based nanoparticles have emerged for applications in cancer radiotherapy in recent years, but few investigations have been carried out for palladium nanoparticles. Herein, palladium nanosheets (Pd NSs), which possess a sheetlike morphology with a diameter of ∼14 nm and a thickness of ∼2 nm, were utilized as a sensitizer to improve the performance of radiotherapy. It was found that Pd NSs alone did not decrease the cell viability after treatment for as long as 130 h, suggesting the excellent cytocompatibility of the nanoagents. However, the viability of cancer cells treated with X-ray irradiation became lower, and the viability became even lower if the cells were co-treated with X-ray and Pd NSs, indicating the radiosensitization effect of Pd NSs. Additionally, compared with X-ray irradiation, the combined treatment of Pd NSs and X-ray irradiation induced the generation of more DNA double-stranded breaks and reactive oxygen species within cancer cells, which eventually caused elevated cell apoptosis. Moreover, in vivo experiments also verified the radiosensitization effect and the favorable biocompatibility of Pd NSs, indicating their potential for acquiring satisfactory in vivo radiotherapeutic effect at lower X-ray doses. It is believed that the present research will open new avenues for the application of noble metal-based nanoparticles in radiosensitization.
Collapse
Affiliation(s)
- Yao-Wen Jiang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Ge Gao
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Hao-Ran Jia
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Xiaodong Zhang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Xiaotong Cheng
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Hong-Yin Wang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| | - Peidang Liu
- Institute of Neurobiology, School of Medicine, Southeast University, Nanjing 210096, P. R. China
| | - Fu-Gen Wu
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P. R. China
| |
Collapse
|
14
|
Holden NE, Coplen TB, Böhlke JK, Tarbox LV, Benefield J, de Laeter JR, Mahaffy PG, O’Connor G, Roth E, Tepper DH, Walczyk T, Wieser ME, Yoneda S. IUPAC Periodic Table of the Elements and Isotopes (IPTEI) for the Education Community (IUPAC Technical Report). PURE APPL CHEM 2018. [DOI: 10.1515/pac-2015-0703] [Citation(s) in RCA: 52] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Abstract
The IUPAC (International Union of Pure and Applied Chemistry) Periodic Table of the Elements and Isotopes (IPTEI) was created to familiarize students, teachers, and non-professionals with the existence and importance of isotopes of the chemical elements. The IPTEI is modeled on the familiar Periodic Table of the Chemical Elements. The IPTEI is intended to hang on the walls of chemistry laboratories and classrooms. Each cell of the IPTEI provides the chemical name, symbol, atomic number, and standard atomic weight of an element. Color-coded pie charts in each element cell display the stable isotopes and the relatively long-lived radioactive isotopes having characteristic terrestrial isotopic compositions that determine the standard atomic weight of each element. The background color scheme of cells categorizes the 118 elements into four groups: (1) white indicates the element has no standard atomic weight, (2) blue indicates the element has only one isotope that is used to determine its standard atomic weight, which is given as a single value with an uncertainty, (3) yellow indicates the element has two or more isotopes that are used to determine its standard atomic weight, which is given as a single value with an uncertainty, and (4) pink indicates the element has a well-documented variation in its atomic weight, and the standard atomic weight is expressed as an interval. An element-by-element review accompanies the IPTEI and includes a chart of all known stable and radioactive isotopes for each element. Practical applications of isotopic measurements and technologies are included for the following fields: forensic science, geochronology, Earth-system sciences, environmental science, and human health sciences, including medical diagnosis and treatment.
Collapse
Affiliation(s)
- Norman E. Holden
- National Nuclear Data Center, Brookhaven National Laboratory , Upton, NY , USA
| | | | | | | | | | | | | | | | - Etienne Roth
- Commissariat à l’énergie atomique (CEA) , Gif-sur-Yvette, France
| | | | - Thomas Walczyk
- Department of Chemistry , National University of Singapore , Singapore , Singapore
| | - Michael E. Wieser
- Department of Physics and Astronomy , University of Calgary , Calgary , Canada
| | | |
Collapse
|
15
|
Abstract
Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β- or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.
Collapse
Affiliation(s)
- Eszter Boros
- Department of Chemistry , Stony Brook University , Stony Brook , New York 11794 , United States
| | - Alan B Packard
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.,Harvard Medical School , Boston , Massachusetts 02115 , United States
| |
Collapse
|
16
|
Guleria M, Kumar C, Das T, Amirdhanayagam J, Sharma R, Sarma HD, Dash A. Studies towards elucidating the potential of 5,10,15,20-tetrakis( p-carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT. MEDCHEMCOMM 2018; 9:657-666. [PMID: 30108956 DOI: 10.1039/c7md00433h] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 02/06/2018] [Indexed: 12/11/2022]
Abstract
Porphyrins, owing to their inherent tendency to accumulate in tumorous lesions, are considered suitable for developing agents for theranostic applications involving tumor diagnosis and targeted tumor therapy. The aim of the present work is to study the potential of a porphyrin derivative namely, 5,10,15,20-tetrakis(p-carboxymethyleneoxyphenyl)porphyrin (SPTA) as a theranostic agent for applications in positron emission tomography (PET) and photodynamic therapy (PDT). SPTA was synthesized in-house following a three-step reaction process and characterized by using spectroscopic techniques, viz. UV-vis, FT-IR, 1H-NMR and 13C-NMR spectroscopy, as well as by mass spectrometry. SPTA was labeled with 68Ga, a generator produced PET radioisotope, and the radiolabeled product was characterized by HPLC. The 68Ga-SPTA complex was prepared with a radiochemical purity of >95% under optimized conditions. The diagnostic potential of 68Ga-SPTA was evaluated by cell uptake studies in two different tumor cell lines (HT1080 and A549) which revealed the affinity of 68Ga-SPTA towards the cancer cells. Biodistribution studies carried out in Swiss mice bearing fibrosarcoma tumors exhibited the accumulation of the radiotracer in the tumor. The therapeutic potential of SPTA was evaluated by determining its photo-cytotoxicity employing the MTT assay in HT1080 and A549 cell lines using three different light doses, which indicated the significant cytotoxicity of SPTA in the presence of light. The present study indicates the possible potential of SPTA in radionuclide imaging as well as in photodynamic therapy (PDT) thus confirming the promising theranostic nature of this porphyrin derivative.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Chandan Kumar
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Tapas Das
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Rohit Sharma
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India
| | - Ashutosh Dash
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| |
Collapse
|
17
|
Ghosh S, Das T, Sarma HD, Dash A. Preparation and Evaluation of 177Lu-Labeled Gemcitabine: An Effort Toward Developing Radiolabeled Chemotherapeutics for Targeted Therapy Applications. Cancer Biother Radiopharm 2017; 32:239-246. [PMID: 28876087 DOI: 10.1089/cbr.2017.2255] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Gemcitabine, a nucleoside analogue, is used as a chemotherapeutic drug for the treatment of a wide variety of cancers. Therefore, radiolabeled gemcitabine may have potential as a radiotherapeutic agent for the treatment of various types of cancers. In the present work, an attempt has been made to radiolabel gemcitabine with 177Lu and study the preliminary biological behavior of 177Lu-labeled gemcitabine in tumor-bearing animal model. EXPERIMENTAL Gemcitabine was coupled with p-NCS-benzyl-DOTA, a bifunctional chelating agent, to facilitate radiolabeling with 177Lu. The p-NCS-benzyl-DOTA-gemcitabine conjugate was radiolabeled with 177Lu, produced in-house and characterized by high-performance liquid chromatography. Tumor targeting potential of the radiolabeled agent was determined by biodistribution studies in Swiss mice bearing fibrosarcoma tumors. RESULTS 177Lu-gemcitabine was prepared with a radiochemical purity of 95.7% ± 0.3% under the optimized reaction conditions. The radiolabeled agent showed adequate in vitro stability in normal saline as well as in human blood serum. Preliminary biological studies revealed rapid and significant accumulation of the radiotracer in the tumorous lesions along with fast clearance of activity from blood and other vital organs/tissue. Although tumor uptake gradually reduced with time, tumor to blood and tumor to muscle ratios were improved due to the comparatively faster clearance of activity from the nontarget organs/tissue. CONCLUSION The present study demonstrates the preliminary potential of 177Lu-gemcitabine for targeted radiotherapy. However, further studies are warranted to assess its potential for radiotherapeutic applications.
Collapse
Affiliation(s)
- Subhajit Ghosh
- 1 Radiopharmaceuticals Division, Bhabha Atomic Research Centre , Mumbai, India .,2 Homi Bhabha National Institute , Anushaktinagar, Mumbai, India
| | - Tapas Das
- 1 Radiopharmaceuticals Division, Bhabha Atomic Research Centre , Mumbai, India .,2 Homi Bhabha National Institute , Anushaktinagar, Mumbai, India
| | - Haladhar D Sarma
- 3 Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre , Mumbai, India
| | - Ashutosh Dash
- 1 Radiopharmaceuticals Division, Bhabha Atomic Research Centre , Mumbai, India .,2 Homi Bhabha National Institute , Anushaktinagar, Mumbai, India
| |
Collapse
|
18
|
Guleria M, Das T, Sarma HD, Banerjee S. Synthesis and bioevaluation of a 177Lu-labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent. J Radioanal Nucl Chem 2015. [DOI: 10.1007/s10967-015-4276-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Zolghadri S, Yousefnia H, Jalilian AR, Fazaeli Y. Production, quality control, biodistribution assessment and preliminary dose evaluation of [177Lu]-tetra phenyl porphyrin complex as a possible therapeutic agent. BRAZ J PHARM SCI 2015. [DOI: 10.1590/s1984-82502015000200011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
<p>Due to interesting therapeutic properties of <sup>177</sup>Lu and tumor avidity of tetraphenyl porphyrins (TPPs), <sup>177</sup>Lu-tetraphenyl porphyrin was developed as a possible therapeutic compound. <sup>177</sup>Lu of 2.6-3 GBq/mg specific activity was obtained by irradiation of natural Lu<sub>2</sub>O<sub>3</sub>sample with thermal neutron flux of 4 × 10<sup>13</sup> n.cm<sup>-2</sup>.s<sup>-1</sup>. Tetraphenyl porphyrin was synthetized and labeled with <sup>177</sup>Lu. Radiochemical purity of the complex was studied using Instant thin layer chromatography (ITLC) method. Stability of the complex was checked in final formulation and human serum for 48 h. The biodistribution of the labeled compound in vital organs of wild-type rats was studied up to 7 d. The absorbed dose of each human organ was calculated by medical internal radiation dose (MIRD) method. A detailed comparative pharmacokinetic study was performed for <sup>177</sup>Lu cation and [<sup>177</sup>Lu]-TPP. The complex was prepared with a radiochemical purity: >97±1% and specific activity: 970-1000 MBq/mmol. Biodistribution data and dosimetric results showed that all tissues receive approximately an insignificant absorbed dose due to rapid excretion of the complex through the urinary tract. [<sup>177</sup>Lu]-TPP can be an interesting tumor targeting agent due to low liver uptake and very low absorbed dose of approximately 0.036 to the total body of human.</p>
Collapse
|
20
|
Motaleb MA, Nassar MY. Preparation, molecular modeling and biodistribution of 99mTc-phytochlorin complex. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-2920-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Waghorn PA. Radiolabelled porphyrins in nuclear medicine. J Labelled Comp Radiopharm 2013; 57:304-9. [PMID: 24353174 DOI: 10.1002/jlcr.3166] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 10/29/2013] [Indexed: 11/09/2022]
Abstract
Amongst tumour-specific substances, hematoporphyrin and synthetic porphyrin derivatives have been widely investigated to identify and delineate neoplastic and malignant tissue. Whilst the tumour localization exhibited by selected porphyrin species has been exploited through photodynamic therapy, several examples of porphyrin derivatives with varied peripheral functionality have been radiolabelled with the aim of developing porphyrin-based nuclear imaging and therapeutic agents. In this review, we look at the approaches and advances in the preparation and uses of such radiolabelled agents for imaging and therapy.
Collapse
Affiliation(s)
- Philip A Waghorn
- CR-UK/MRC Gray Institute for Radiation Oncology and Biology, Department of Oncology, University of Oxford, Oxford, OX3 7LE, UK; Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK
| |
Collapse
|
22
|
Chakraborty S, Das T, Sarma HD, Banerjee S. Effect of lipophilicity on biological properties of 109Pd-porphyrin complexes: a preliminary investigation. J PORPHYR PHTHALOCYA 2012. [DOI: 10.1142/s1088424611004427] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The present study is designed to investigate the effect of lipophilicity of 109Pd-porphyrin complexes on their biological properties which were evaluated in tumor-bearing animal model. The insight obtained could be utilized to develop other radiometalated porphyrin complexes with optimum tumor uptake and tumor to background ratio as potential agents for targeted tumor therapy. 109Pd was produced by thermal neutron bombardment on enriched (in 109Pd) metallic palladium target at a flux of 3 × 1013 n/cm2.s for 3 d. 109Pd complexes of three different porphyrin derivatives, namely, 5,10,15,20-tetrakis[3,4- bis(carboxymethyleneoxy)phenyl]porphyrin(I), 5,10,15,20-tetrakis[3,4-bis(carboethoxymethyleneoxy)phenyl]porphyrin(II) and 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin(III), which differ in their peripheral substituents, were synthesized. The biological behavior of the complexes was studied in Swiss mice bearing fibrosarcoma tumors. 109Pd was produced with a specific activity of ~1.85 GBq/mg (50 mCi/mg) and radionuclidic purity of 100%. All the 109Pd complexes were obtained in high yield (>97%) and they exhibited satisfactory in vitro stability at room temperature. The lipophilicity of the complexes follows the order 109Pd-II ≫ 109Pd-III > 109Pd-I. Biodistribution studies revealed that the most lipophilic 109Pd-II complex exhibited highest initial tumor uptake but poor tumor/liver ratio, while 109Pd-III complex exhibited the best tumor/liver ratio with reasonably good tumor accumulation. The lipophilicity of 109Pd-porphyrin complexes was found to have considerable effect on their biological characteristics and radiometal-porphyrin complexes with optimum tumor uptake and adequately high tumor to background ratio could be synthesized by optimization of the lipophilicity through proper selection of peripheral substituents.
Collapse
Affiliation(s)
- Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India
| | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India
| | - Sharmila Banerjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400085, India
| |
Collapse
|
23
|
Yang Y, Song H, Song H, Zhao W, Pu M. Preparation of 99mTc(CO)3-TPPS4 and its biological behavior evaluation. J PORPHYR PHTHALOCYA 2012. [DOI: 10.1142/s1088424611003240] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
99mTc(CO)3-TPPS4 was prepared via the precursor [99mTc(CO)3(H2O)3]+ and a preliminary investigation on its stability and behavior in Hep2 tumor cells and hepatoma-bearing mice were conducted. Labeling yield and stability of 99mTc(CO)3-TPPS4 was radioactively analyzed by paper chromatography. Hep2 tumor cells were incubated with 99mTc(CO)3-TPPS4 complex system in the substrate and isolated from the substrate for radioactivity count. Then 99mTc(CO)3-TPPS4 complex system was intravenously injected in hepatoma-bearing mice and directly injected in tumor tissue of the mice. Mice were photographed using SPECT. Labeling yields of 99mTc(CO)3-TPPS4 were more than 90% at pH = 7–8, 30 min, in a boiling bath, and it was stable for at least 14 h at pH = 2–8, rt ~95 °C. The uptake of 99mTc(CO)3-TPPS4 in HepG2 tumor cells was only 3–4% with the maximum uptake-time of 20 min. The SPECT images of hepatoma-bearing nude mice showed no uptake or little retention of 99mTc(CO)3-TPPS4 in the tumor tissue. Then the differences between 99mTc(CO)3-TPPS4 and TPPS4 were analyzed by fluoroscopy and molecular structure. It was found that the paper chromatography, HepG2 tumor cell uptake and the optimized porphyrin ring conformation of 99mTc(CO)3-TPPS4 were quite different from those of TPPS4. It was indicated that 99mTc(CO)3-TPPS4 had no uptake or little retention in hepatic tumors, unlike those biological behaviors of TPPS4. This may be due to the modification of porphyrin ring conformation of TPPS4 by 99mTc(CO)3 core.
Collapse
Affiliation(s)
- Yuqing Yang
- Institute of Nuclear Physics and Chemistry, Mianyang, Sichuan 621900, China
| | - Hu Song
- Institute of Nuclear Physics and Chemistry, Mianyang, Sichuan 621900, China
| | - Hongtao Song
- Institute of Nuclear Physics and Chemistry, Mianyang, Sichuan 621900, China
| | - Weiwei Zhao
- Department of Nuclear Medicine, Sichuan University, Chengdu, Sichuan 610041, China
| | - Manfei Pu
- Institute of Nuclear Physics and Chemistry, Mianyang, Sichuan 621900, China
| |
Collapse
|
24
|
Das T, Chakraborty S, Sarma HD, Banerjee S, Venakatesh M. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy. Nucl Med Biol 2010; 37:655-63. [DOI: 10.1016/j.nucmedbio.2010.02.007] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2009] [Revised: 02/09/2010] [Accepted: 02/28/2010] [Indexed: 10/19/2022]
|
25
|
Sarma HD, Das T, Banerjee S, Venkatesh M, Vidyasagar PB, Mishra KP. Biologic Evaluation of a Novel 188Re-Labeled Porphyrin in Mice Tumor Model. Cancer Biother Radiopharm 2010; 25:47-54. [DOI: 10.1089/cbr.2009.0675] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Haladhar D. Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Sharmila Banerjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Meera Venkatesh
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | | | - Kaushala P. Mishra
- Radiation and Cancer Biology Laboratory, Department of Life Science, University of Mumbai, Mumbai, India
| |
Collapse
|
26
|
|